Jules Evans of The Challenging Psychedelic Experiences Project discusses the project and what he and his co-researchers hope to learn from the data they collect.
Read moreThe Key to Happiness
Researchers have followed over 700 people since 1938 to find the keys to happiness.
Read morePsychedelics and Traumatic Brain Injury
DMT and a Shared Alien Universe?
As The New Republic reports, the Colorado-based psychedelics startup Medicinal Mindfulness is currently seeking approval from the Food and Drug Administration to study what it's calling DMTx, an extended-state, intravenous drip version of DMT that will induce in users trips far longer than the roughly five-to-ten minute experiences the drug typically provides.
DMT carries with it a ton of intriguing qualities, including that studies suggest our brains produce the drug naturally and that those who have taken it often experience variations on the same theme: entering what seems to be another plane or dimension replete with its own ethereal beings, sometimes referred to as "machine elves," who are there to welcome them.
Read morePsilocybin and Bipolar Disorder
Researchers collected survey data from over 500 people with bipolar disorder about their experiences using psilocybin, the results of which were published in a previous paper.
Read moreBelief Changes with Psychedelics
In a recent study, published on Nov. 1 in the Journal of Psychopharmacology, experts from the Johns Hopkins Center for Psychedelic and Consciousness Research explored belief changes related to psychedelic experiences.
They found that a single psychedelic experience increased a range of nonphysicalist beliefs as well as beliefs about consciousness, meaning and purpose.
Read morePsychedelics and the Brain-New Research
Psychedelic drugs may reopen critical learning periods in the brain.
Recent research shows that in adult mice, psychedelic drugs including LSD, ketamine and psilocybin have been shown to reopen the brain to a critical window for social learning usually only seen in adolescents.
Read morePsilocybin and Antidepressants
New research suggests that antidepressants can diminish the effects of psilocybin.
Read moreRecent Research on Psilocybin Gives Mixed Results
Compass Pathways published the long awaited results of its phase 2 clinical trial for the treatment of depression with psilocybin–assisted psychotherapy in the New England Journal of Medicine.
Psilocybin showed rapid antidepressant effects for most patients, but only 1 in 5 participants showed significant improvement at 12 weeks.
Read moreMDMA and Eating Disorders
MDMA-assisted psychotherapy shows promise in the treatment of eating disorder symptoms.
Read more